MEDI - ETF AI Analysis
Top Page
Harbor Health Care ETF (MEDI)
Rating:62Neutral
Price Target:―
Positive Factors
Focused Health Care Exposure
The fund is almost entirely invested in health care companies, giving investors targeted access to this defensive and long-term growth sector.
Strong Performers Among Top Holdings
Several of the larger positions, such as Ascendis Pharma, Legend Biotech, and Vaxcyte, have shown strong recent performance, helping offset weaker names in the portfolio.
Recent Short-Term Rebound
Despite a weak year so far, the ETF has shown a solid gain over the past month, suggesting some recovery in its holdings.
Negative Factors
High Stock Concentration
A small number of companies, especially Eli Lilly and Ascendis Pharma, make up a large share of the fund, increasing the impact if any of these stocks struggle.
Narrow Sector and Geographic Focus
With almost all assets in U.S. health care stocks, the ETF offers little diversification across sectors or countries, making it more sensitive to issues affecting that area of the market.
High Expense Ratio
The fund charges a relatively high fee, which can eat into returns over time compared with lower-cost ETFs.
MEDI vs. SPDR S&P 500 ETF (SPY)
AUM27.62M
RegionGlobal
Expense Ratio0.80%
Beta0.75
IssuerHarbor
Inception DateNov 17, 2022
Dividend Yield0.25%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,017
30 Day Avg. Volume5,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.04Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDI Summary
The Harbor Health Care ETF (MEDI) is a fund that focuses on the health care sector rather than tracking a broad market index. It invests mainly in U.S. health care companies involved in drugs, medical devices, and health services. Well-known holdings include Eli Lilly and AbbVie, along with other biotech and medical technology firms. Someone might invest in MEDI to seek growth from medical innovation and an aging population while getting diversification across many health care names. A key risk is that it is heavily concentrated in health care stocks, so its value can swing with changes in this single sector.
How much will it cost me?The Harbor Health Care ETF (MEDI) has an expense ratio of 0.8%, meaning you’ll pay $8 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care companies rather than tracking a broad index.
What would affect this ETF?The Harbor Health Care ETF (MEDI) could benefit from increasing global demand for health care services driven by aging populations, technological advancements, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact funding for health care initiatives or the profitability of its top holdings like Eli Lilly and AbbVie. Its global exposure also makes it sensitive to international health policies and economic conditions.
MEDI Top 10 Holdings
MEDI is very much a health‑care pure play, and it leans heavily on a few big names. Eli Lilly sits in the driver’s seat but has been losing steam lately, which can weigh on returns. Intuitive Surgical and AbbVie are also sizable positions, yet both have been lagging, adding to the drag. On the brighter side, smaller biotech holdings like Legend Biotech and Vaxcyte have been rising, injecting some excitement into the mix. With a global health‑care focus and a tilt toward innovative drug and device makers, this ETF is concentrated but clearly thematic.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 19.70% | $5.44M | $867.01B | 6.74% | 72 Outperform | |
| Ascendis Pharma | 14.59% | $4.03M | $14.03B | 40.23% | 46 Neutral | |
| Legend Biotech | 5.23% | $1.44M | $4.44B | -29.94% | 46 Neutral | |
| Vaxcyte | 4.92% | $1.36M | $8.75B | 76.09% | 50 Neutral | |
| Intuitive Surgical | 4.73% | $1.31M | $169.58B | -5.77% | 78 Outperform | |
| AbbVie | 4.54% | $1.25M | $355.43B | 11.41% | 66 Neutral | |
| Rhythm Pharmaceuticals | 3.96% | $1.09M | $5.82B | 35.32% | 59 Neutral | |
| Insmed | 3.91% | $1.08M | $31.05B | 108.57% | 43 Neutral | |
| Abivax SA Sponsored ADR | 3.40% | $938.35K | $9.08B | 1530.59% | 60 Neutral | |
| Danaher | 2.42% | $667.67K | $126.39B | -9.12% | 75 Outperform |
MEDI Technical Analysis
Negative
―
Price Trends
30.21
Negative
30.87
Negative
29.77
Negative
Market Momentum
0.06
Negative
45.61
Neutral
30.71
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 29.78, equal to the 50-day MA of 30.21, and equal to the 200-day MA of 29.77, indicating a bearish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 45.61 is Neutral, neither overbought nor oversold. The STOCH value of 30.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDI.
MEDI Peer Comparison
Comparison Results
Performance Comparison
MEDI
Harbor Health Care ETF
29.59
3.75
14.51%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents